New hope for rare leukemia: targeted combo trial launches
NCT ID NCT06313437
First seen Apr 05, 2026 · Last updated May 15, 2026 · Updated 7 times
Summary
This early-phase trial tests a new drug called revumenib alongside standard chemotherapy and a targeted therapy (midostaurin) for adults with a specific genetic form of acute myeloid leukemia (AML). The goal is to find a safe dose that improves remission rates. About 22 newly diagnosed patients aged 18 to 74 will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Yale Cancer Center
RECRUITINGNew Haven, Connecticut, 06150, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.